Literature DB >> 700900

Oncogenicity of Friend-virus-infected cells: determination of origin of spleen colonies by the H-2 antigens as genetic markers.

F Wendling, P E Tambourin.   

Abstract

Spleen cells from mice infected with Friend leukemia virus (FLV) inoculated by the intravenous route give rise to macroscopically visible colonies in the spleens of normal F1 histocompatible hybrid hosts. A study of H-2 antigens as generic markers for identification of strains of origin of cells constituting the spleen colonies was undertaken. The standard cytotoxic test was demonstrated to be suitable for characterizing the H-2 antigens present on the surface of spleen cells from normal of FLV-leukemic parents of F1 hybrid mice. Individual colonies dissected out of the spleen of (C3HxC57B6/6) F1 recipients (H-2k/H-2b), 10 days after the intravenous graft of FLV-infected spleen cells of C3H origin (H-2k), were all sensitive to anti-C57BL/6 antibodies. In the same way, colonies obtained from the spleens of (DBA/2xC57BL/10) F1 recipients (H-2d/H-2b) grafted with DBA/2 leukemic spleen cells (H-2d) were all sensitive to both anti-H-2b and anti-H-2d antibodies. These results directly prove that the main cell population constituing a spleen colony arises from the recipient. The authors conclude that the spleen colonies do not result from the neoplastic proliferation of injected donor cells but rather from the multiplication of host cells transformed by Friend virus produced by the grafted cells.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 700900     DOI: 10.1002/ijc.2910220418

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Kinetics of the development of protective immunity in mice vaccinated with a live attenuated retrovirus.

Authors:  U Dittmer; B Race; K J Hasenkrug
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs.

Authors:  Anke R M Olbrich; Simone Schimmer; Klaus Heeg; Koen Schepers; Ton N M Schumacher; Ulf Dittmer
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  Hemopoietic stem cells and target cells in murine-virus-induced leukemias.

Authors:  H J Seidel
Journal:  J Cancer Res Clin Oncol       Date:  1982       Impact factor: 4.553

4.  Role of interleukin-4 (IL-4), IL-12, and gamma interferon in primary and vaccine-primed immune responses to Friend retrovirus infection.

Authors:  U Dittmer; K E Peterson; R Messer; I M Stromnes; B Race; K J Hasenkrug
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

5.  Protection against establishment of retroviral persistence by vaccination with a live attenuated virus.

Authors:  U Dittmer; D M Brooks; K J Hasenkrug
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

6.  Preinfection treatment of resistant mice with CpG oligodeoxynucleotides renders them susceptible to friend retrovirus-induced leukemia.

Authors:  Anke R M Olbrich; Simone Schimmer; Ulf Dittmer
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Effects of type I interferons on Friend retrovirus infection.

Authors:  Nicole Gerlach; Simone Schimmer; Siegfried Weiss; Ulrich Kalinke; Ulf Dittmer
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

8.  Characterization of a live-attenuated retroviral vaccine demonstrates protection via immune mechanisms.

Authors:  U Dittmer; D M Brooks; K J Hasenkrug
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

9.  Normal and Friend virus specific cell compartments in Friend leukemia characterized by their sensitivity to actinomycin D in vivo.

Authors:  H J Seidel; L Kreja; U Opitz; G Steinheider; P Eberle
Journal:  Blut       Date:  1981-11

10.  Emergence of tumorigenic cells during the course of Friend virus leukemias.

Authors:  F Wendling; F Moreau-Gachelin; P Tambourin
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.